Product
Losartan + Hydrochlorothiazide
Aliases
Losartan + hydrochlorothiazide in fixed dose, losartan potassium (+) hydrochlorothiazide, LOS/HYDROCHLO
4 clinical trials
3 indications
Indication
Essential hypertensionIndication
HypertensionIndication
Metabolic DisorderClinical trial
Confirmatory Study of the Efficacy and Safety of the Combination of Losartan / Chlorthalidone vs Losartan / Hydrochlorothiazide in the Treatment of Patients With Essential Arterial HypertensionStatus: Completed, Estimated PCD: 2023-08-15
Clinical trial
BP-EASE-A 12-Week, Multicenter, Open-Label, Randomized, Controlled Trial To Compare The Effectiveness of Losartan 50 mg/HCTZ 12.5 mg Titrated as Needed to Losartan 100 mg/HCTZ 25 mg or Valsartan 160 mg/HCTZ 25 mg, in Patients With Essential Hypertension Who Have Not Achieved Target Blood Pressure WithStatus: Completed, Estimated PCD: 2009-04-01
Clinical trial
52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic SyndromeStatus: Completed, Estimated PCD: 2008-01-01
Clinical trial
A Randomized, Open-label, Comparative, Non-inferiority, Multicenter Study to Compare Efficacy of Losartan Potassium Group and Carvedilol Group on Arterial Stiffness in Essential Hypertension PatientsStatus: Completed, Estimated PCD: 2009-09-01